Single‐dose psilocybin superior to placebo for MDD in community setting

Major depressive disorder (MDD) affects about 300 million people worldwide. About one‐third of these have treatment‐resistant depression (TRD), commonly defined as a failure to respond to two antidepressants. Although these conditions represent a major public health problem, access to specialized treatments is limited.

Publication Details

Journal
The Brown University Psychopharmacology Update
Published
2026-11-14
DOI
https://doi.org/10.1002/pu.31520
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Single‐dose psilocybin superior to placebo for MDD in community setting

The Brown University Psychopharmacology Update
Psychedelics and Drug Studies
article

Single‐dose psilocybin superior to placebo for MDD in community setting

article en

Abstract

Major depressive disorder (MDD) affects about 300 million people worldwide. About one‐third of these have treatment‐resistant depression (TRD), commonly defined as a failure to respond to two antidepressants. Although these conditions represent a major public health problem, access to specialized treatments is limited.

The Brown University Psychopharmacology UpdateVol. 37(12)
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon